WIRE — SPECIAL REPORT | URN | A sub-study of the landmark clinical trial evaluating the safety and efficacy of the twice-yearly injectable HIV prevention drug, Lenacapavir, has found that it provides 100 percent protection against HIV infection among pregnant and breastfeeding women using it as pre-exposure prophylaxis (PrEP). The Phase 3 PURPOSE 1 trial results, published … The post STUDY: HIV injectable drug offers pregnant, lactating mothers 100% protection appeared first on The Independent Uganda:.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.